ARTICLE | Emerging Company Profile
Lundbeckfonden-backed start-up believes at-home oral therapy would offer benefits over injectables for genetically defined patients with dementia
By Paul Bonanos, Director of Biopharma Intelligence
February 28, 2024 2:55 AM UTC
Backed since its inception by Lundbeckfonden BioCapital, Danish start-up Vesper Bio has reached the clinic with what could be the first oral sortilin inhibitor to treat a genetically identified subset of patients with frontotemporal dementia.
With roots at Aarhus University, Vesper Bio ApS hopes to show that by inhibiting SORT1 with a brain-penetrant molecule, the company’s VES001 can maintain levels of PGRN and thus preserve neurological function in patients with heterozygous mutations in the GRN gene…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650887/vesper-bio-a-sortilin-targeting-pill-to-treat-neurological-disease